| 经皮冠状动脉介入围术期抗血小板药物的选择 |
| |
| 引用本文： | 马丽萍,杨雅薇,李攀,陈韬,刘宇,柳俊梅. 经皮冠状动脉介入围术期抗血小板药物的选择[J]. 药学服务与研究, 2014, 0(4): 241-244 |
| |
| 作者姓名： | 马丽萍 杨雅薇 李攀 陈韬 刘宇 柳俊梅 |
| |
| 作者单位： | 第二军医大学长海医院心血管内科,上海200433 |
| |
| 基金项目： | 国家科技重大专项重大新药创制资助项目（2011ZX09302-002-02） |
| |
| 摘 要： | 经皮冠状动脉介入治疗（percutaneous coronary intervention,PCI）围术期抗血小板治疗可明显降低PCI术后心血管事件及病死率。近年大量循证医学证据不断涌现,新的抗血小板药物不断研制开发,但临床如何权衡支架内血栓形成及出血的风险,制定个体化的治疗方案,对降低PCI围术期心脏事件至关重要。本文复习近年相关资料,为临床PCI围术期规范化使用抗血小板药物提供借鉴。
|
| 关 键 词： | 血管成形术,气囊,冠状动脉 介入治疗 围手术期 血小板聚集抑制剂 综述 |
Selection of platelet aggregation inhibitors in percutaneous coronary intervention perioperation |
| |
| MA LiPing,YANG YaWei,LI Pan,CHEN Tao,LIU Yu,LIU JunMei. Selection of platelet aggregation inhibitors in percutaneous coronary intervention perioperation[J]. Pharmaceutical Care and Research, 2014, 0(4): 241-244 |
| |
| Authors: | MA LiPing YANG YaWei LI Pan CHEN Tao LIU Yu LIU JunMei |
| |
| Affiliation: | (Department of Cardiovasology, Changhai Hospital, Second Military Medical University, Shanghai 200433 ,China) |
| |
| Abstract: | Perioperative anti platelet therapy can significantly reduce cardiovascular events and mortality of patients after percutaneous coronary intervention（PCI）. With growing evidences of evidence based medicine and development of new anti- platelet agents in recent years, it is of vital importance to balance risks of thrombosis and hemorrhage, to develop personalized treatment regimen and to reduce cardiovascular events during PCI perioperation. This paper is a review of recent progress in anti-platelet therapy in PCI, which could provide evidence for standard medication of anti platelet agents in PCI perioperation. |
| |
| Keywords: | angioplasty,balloon,coronary intervention perioperative period platelet aggregation inhibitors review |
| 本文献已被 维普 等数据库收录！ |
|
